CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Millions		6 Months Ended
		Jun. 28, 2020	Jun. 30, 2019
Operating Activities
Net income before allocation to noncontrolling interests	[1],[2],[3],[4]	$ 6,845	$ 8,945
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:
Depreciation and amortization	[2]	2,469	3,073
Asset write-offs and impairments	[2]	58	178
TCJA impact	[2],[5]	0	(285)
Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed	[2]	(6)	0
Deferred taxes from continuing operations	[2]	71	(160)
Share-based compensation expense	[2]	258	384
Benefit plan contributions in excess of expense/income	[2]	(418)	(313)
Other adjustments, net	[2]	(361)	(462)
Other changes in assets and liabilities, net of acquisitions and divestitures	[2]	(2,229)	(7,051)
Net cash provided by operating activities	[2]	6,688	4,309
Investing Activities
Purchases of property, plant and equipment	[2]	(942)	(939)
Purchases of short-term investments	[2]	(5,141)	(4,063)
Proceeds from redemptions/sales of short-term investments	[2]	4,595	6,001
Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less	[2],[6]	(11,949)	4,717
Purchases of long-term investments	[2]	(168)	(123)
Proceeds from redemptions/sales of long-term investments	[2]	536	142
Acquisitions of intangible assets	[2]	(33)	(267)
Other investing activities, net	[2]	19	179
Net cash provided by/(used in) investing activities	[2]	(13,082)	5,648
Financing Activities
Proceeds from short-term borrowings	[2]	12,352	3,956
Principal payments on short-term borrowings	[2]	(13,166)	(2,375)
Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less	[2]	(2,273)	2,719
Proceeds from issuance of long-term debt	[2],[6]	16,606	4,942
Principal payments on long-term debt	[2]	(2,181)	(5,355)
Purchases of common stock	[2]	0	(8,865)
Cash dividends paid	[2]	(4,216)	(4,047)
Proceeds from exercise of stock options	[2]	158	248
Other financing activities, net	[2]	(321)	(541)
Net cash provided by/(used in) financing activities	[2]	6,959	(9,318)
Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents	[2]	(70)	(28)
Net increase in cash and cash equivalents and restricted cash and cash equivalents	[2]	495	612
Cash and cash equivalents and restricted cash and cash equivalents, beginning	[2]	1,350	1,225
Cash and cash equivalents and restricted cash and cash equivalents, end	[2]	1,845	1,837
Cash paid (received) during the period for:
Income taxes	[2]	1,290	2,136
Interest paid	[2]	910	809
Interest rate hedges	[2]	$ (66)	$ (72)

[1] Amounts may not add due to rounding.

[2] Amounts may not add due to rounding.

[3] Amounts may not add due to rounding.

[4] Amounts may not add due to rounding.

[5] As a result of the enactment of the TCJA in December 2017, Pfizer’s Provision/(benefit) for taxes on income for the six months ended June 30, 2019 was favorably impacted by approximately $285 million, primarily as a result of additional guidance issued by the U.S. Department of Treasury.

[6] Includes $11.4 billion of proceeds from the Upjohn long-term debt issuances in the second quarter of 2020, which are included in Restricted short-term investments in the condensed consolidated balance sheet. For additional information, see Notes 7A. Financial Instruments: Fair Value Measurements and Financial Instruments: 7D. Long-Term Debt).